Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Profitable gold producer, PPS is too low. Looking forward to Q2 fins.
Newmed, those were good articles. I read them both for AR for compassionate care
Replying to your post. The last two sentences. LOL
Baldness? Bosley, Hair club for Men
LOL, "cannabis cures baldness" That is funny. As you say Doc, oh wait, didn't someone else already do that?
Question for anyone. How would DeZanger renew the MILV business license in Nevada? Sharon K. Miller was the sole incorporator in 2005 and according to the document, the Nev. business license is non-transferable. NBI is incorporated in Florida.
I hope DeZanger is in the process of changing the ticker to NBI. IMO that would be a good move.
All of these guys came with NBI or were brought on board by NBI, right?
Carmine, Is it possible that DeZanger is one of the people who got taken on the R/M. None of the people who were associated with MILV appear to have any ownership anymore.
Is she related to the CFO, COO, Director?
Robert DeZanger, III President and Chairman of the Board
Mr. DeZanger is a recognized experienced executive, consultant and business professional. He has been managing various businesses and has been providing financial, sales and marketing, and consulting services to corporations both domestic and abroad and to foreign governments and their dignitaries. Mr. DeZanger brings the company a wealth of over 25 years experience in sales and marketing, in project management, as well as a vast network of senior management contacts with suppliers and providers of services that will prove to be invaluable to the Company.
Richard C. Weiner, CFO, COO, Director
Mr. Weiner has over 30 years of senior management experience in both financial and operational positions with various corporations including, Vital Products Company, Quality Group and National Security Title, Regional Construction and Kahzam Inc. In those positions, Mr. Weiner has not only overseen operational management, sales, purchasing, customer service and personnel staffing responsibilities, but also the development and implementation of hardware and software systems. He also has proven abilities to provide critical thinking in recognizing potential problems, developing viable alternatives and implementing cost effective actions. All coupled with a commitment to continuous process improvement.
Most recently served as both the CFO and COO of Madison Ave Media Boca Raton FL, Mr. Weiner oversaw all finances and operations in the continuing expansion of that business.
Lisa Zuck, Secretary, Treasurer, Director
Ms. Zuck graduated from Cornell University with a degree in Industrial and Labor Relations. Since then she has assisted many companies in the management of their labor forces. She has worked with such companies as: Union Carbide, MGM/UA Entertainment, Consolidated Controls and Ford Motor.
Chris Loso, Director
Since 2004 Mr. Loso has been employed by Henry Schein as a laboratory sales specialist. Henry Schien Inc., is a FORTUNE 500® company, a member of the NASDAQ 100® Index and is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners.
Gerald D. Brown, Director
Mr.Brown is the inventor of Nature’s Bioceuticals Formulas. The formulas that he has developed were not developed with the idea of commercialization. They were developed to help family and friends in his home town.
Donald Newman, DDS , Director
Dr. Newman owns and operates a successful holistic dental practice, Tower Dental, in Boca Raton Florida. He is an active member of The South Palm Beach Dental Society, American Dental Holistic Society, and The Gerson Institute.
Stuart D. Cooper, CPA, Director
Stuart D. Cooper, Certified Public Accountant, is a respected Financial Consultant and Auditor in the Public Companies, Securities Regulatory Compliance, and Regulatory Compliance Arena for financial institutions. He has aided many companies in structuring their financial transactions, obtaining access to capital and where applicable, bringing them to the public markets.
Dr. Nancy Lord, Counsel & Advisor
DR. Lord is a Medical Doctor (Not licensed to practice in the state of Nevada) and Attorney. Her knowledge of medicine, natural supplements and patent law is of great assistance to the company. Prior to being appointed as a director, Dr. Lord was retained by Nature’s Bioceuticals to draft and file the patent application for our Breathing Formula. Aside from her duties as an advisor, Dr. Lord will continue to be of Counsel to the company and shall be paid her normal legal fees for doing so.
Currently, Cannabis Science has its cannabis-based high quality extract formulations available in Pueblo and Denver Colorado through licensing agreements. As well, The Company has signed a licensing deal with Apothecary Genetics in California to provide the same full circle operations required under State regulated medical cannabis laws to provide California State licensed medical cannabis patients its formulations.
The Company has been receiving outstanding feed back from the current patients using its formulations for Skin Cancer as documented on the www.cannabisscience.com website.
CBIS - http://ih.advfn.com/p.php?pid=nmona&article=52564397
Cannabis Science President & CEO, Dr. Robert Melamede Ph.D.
Dr. Bob Melamede stated “Cannabis Science is excited that we are developing profit centers that will come online and create revenue in 2012. In addition to the revenues that we believe will be created with the Cannabis Extract Based prescription medicines and over-the-counter formulations, Cannabis Science has the ability to generate revenues now through the partnership with Vincent Mehdizadeh of Medical Dispensing Solutions, and consulting revenues Kaneabis acquisition. It is our goal to self- fund the FDA IND application and approval process as much as possible, that funding is generated from these additional profit centers.”
http://ih.advfn.com/p.php?pid=nmona&article=52131959
CBIS
CBIS reported 116,135 revenue in the first quarter. It's not broken down to say Marisol. So what does that prove? You can't prove where it came from unless you call and ask.
1/2gr. syringe oil $20.00
Clearly labeled Cannabis Science inc.
For topical and internal.
I've been here watching to see what others have to say.
Today, Marisol said the had the one I mentioned in the post.
Thank you.
Why the 27th? If they file financials they may not come out for 4 weeks. I want to see if they report any sales for the 2nd quarter.
K Dog - What did you really think of the Las Vegas show? What happened to the third product? Did you get a look at it? It's not showing on the NBI website.
You give me way too much credit. I just thought it was interesting. Glad you made a bundle on the two you owned.
Call Marisol and ask them. That's who is selling it.
The successful release of the second Cannabis Science brand formulation.
Manufacturing and packaging has been completed and is now available through Marisol Therapeutics for patient usage.
PHONE: 719-547-4000
ADDRESS: 922 Kimble Drive Pueblo West, CO 81007
1/2gr. syringe oil $20.00
Clearly labeled Cannabis Science inc.
For topical and internal.
It is quiet, I think you are right.
If cannabis was a new discovery (a plant that wasn't called marijuana) and it had been proven effective by multiple studies for multiple uses, we wouldn't be able to hold it back.
Interesting isn't it? -- that well-know high-powered people want to be associated with Dr. Melameade and the science that cures cancer as well as many other life threatening conditions and diseases.
Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN). CBIS
AGCZ - The report for the first quarter ended March 31, 2012 shows total revenues of $1,269,965 compared to revenues of $705,915 for the first quarter last year. This is an increase of $564,050 or 80% over the prior year. Net profits for the period ended March 31, 2012 were $202,176 compared to $105,250 last year, an increase of $96,926 or 92%. This increase in profits was obtained despite increases in wages and salaries from $82,276 to $148,756 and an increase in materials and mining supplies from $80,317 to $193,976. The increases in expenses for the first quarter are a result of increased production that will
be reported in the 2nd quarter of 2012.
AGCZ profits were up Q1 and expected to be higher in Q2. AGCZ has a Healthy 3:1 asset to debt ratio with over $2 mil in assets.
In the next thirty days we will have the Q2 financials. I think we will see their revenue increasing as it did for Q1. AGCZ
Loyal, I agree with you.
What is a perp team?
Studies have shown that it reduces pressure in the eyes that cause blindness. Glaucoma is on the list of uses for medical marijuana in some states. Maybe cannabis was in the mud paste that Jesus used. CBIS
It might cure a leper. Cannabis seems to cure cold sores and we know it cures skin cancer. That's a big market. Maybe CBIS can add that to their research.
On February 9, 2012, the Company signed a license agreement with Apothecary Genetics Investments LLC. to produce several Cannabis Science Brand Formulations for the California medical cannabis market. As well, Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding. The Company earned a $25,000 license fee under the agreement for the period ended March 31, 2012.
It’s a seller’s market right now, meaning if you’ve got a product to sell that could potentially replace some glaring gaps that have opened up in the big pharma pipeline as the result of a slew of patent expirations, then you’re holding the leverage to hold out and wait for the best deal. Take some recent examples as evidence; GlaxoSmithKline (NYSE:GSK), for instance, made international headlines with an offer to acquire Human Genome Sciences, Inc. (NASDAQ:HGSI). That bid has since gone hostile when Human Genome demanded a better deal. Illumina, Inc. (NASDAQ:ILMN) also rejected two offers from Roche Holding (PINK:RHHBY) – one for $44.50/share and the other for $51/share — and Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) turned away Bristol-Myers Squibb Company (NYSE:BMY) earlier this year on a $3.5 billion, $22/share offer.
Given the boldness with which the potentially-acquired company held out in each case, it’s understandable why smaller companies with potential blockbusters in their belts would also figure to play a significant role in the merger and acquisition arena in due time.
http://marketplayground.com/2012/07/10/buyout-talk-catalysts-and-clinical-results-can-move-these-healthcare-stocks-amrn-gsk-hgsi-ilmn-rhhby-amln-bmy-pbth-teva-lptn-pfe-ssh-mric-si-bsx-ctso/#more-23868
No, I think you've covered it. I've also noticed several big pharmas making offers to buy some otc medical companies. Maybe eventually GNTA will be one of those companies.
DENVER (BUSINESS WIRE) -- Cannabis Science, Inc. (OTCBB; CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the successful release of the second Cannabis Science brand formulation. The Company has been receiving a constant flow of inquires via its website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer patients seeking extract-based formulations for topical or internal use have frequently contacted Cannabis Science. Manufacturing and packaging has been completed and is now available through Marisol Therapeutics for patient usage.
PHONE: 719-547-4000
ADDRESS: 922 Kimble Drive Pueblo West, CO 81007
Chris Stubbs' work goals include
FDA approval of MMJ.
CBIS
CBIS
Little pharma -Big Visions
Like most businesses in the medical marijuana industry, Cannabis Science is out to change the face of medicine. Unlike your standard center, however, this company is doing it in the lab.
CBIS - Also at the helm is Chris Stubbs, 27, Cannabis Science's lab director, whose job entails recruiting people for the company's current 20-member team, and helping run the labs. Like all other employees, Stubbs also researches partnerships, including last month's Montana Pain Management acquisition. He says Cannabis Science receives numerous inquiry requests for partnerships. "It's almost too hard to handle right now."
See Pollux post #72440
If CBIS didn't do research would they need a lab? Would CBIS need 20 people working in the lab? Would it be a $7 to $10 million dollar business? I they weren't developing medicine and other products, would they need clinical trials? What is the picture of Chris Stubbs working and running the lab?
MRI Interventions Inc. (OTC:MRIC) is another company whose share price has registered some nice recent gains as its MRI-enhancing device, ClearPoint, allows the medical community to conduct less-invasive procedures on the brain. MRIC is also developing its ClearTrace system to augment existing MRI suites to conduct less-invasive procedures of the heart and Siemens AG (NYSE:SI) is already on board as a partner for its development. Another unique collaboration with Boston Scientific Corporation (NYSE:BSX) identifies this company as a buyout play, once again.
http://marketplayground.com/2012/07/10/buyout-talk-catalysts-and-clinical-results-can-move-these-healthcare-stocks-amrn-gsk-hgsi-ilmn-rhhby-amln-bmy-pbth-teva-lptn-pfe-ssh-mric-si-bsx-ctso/#more-23868